Skip to main content

Table 1 The response of primary and metastatic lesions to gefitinib in responders

From: Clinical benefit of readministration of gefitinib for initial gefitinib-responders with non-small cell lung cancer

Site No. of patients No. improved No. of patients with target lesion Average tumor shrinkage of target lesion (%, mean ± SD)
Primary lesion 27 27 21 46.5 ± 19.4
Metastatic lesion     
   Intrapulmonary 12 12 9 73.8 ± 30.6
   Liver 4 4 3 47.3 ± 21.6
   CNS 4 4 2 65.0 ± 21.2
   Bone 8 0   
   Pleural effusion 6 5   
   Others 2 2   
  1. CNS, central nervous system